Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling
Authors:
- 1 April 2005
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 288 (4) , H1997-H2005
Abstract
Angiotensin receptor blockers (ARBs) reduce adverse left ventricular (LV) remodeling and improve LV function and survival when started postmyocardial infarction (MI). ARBs also reduce ventricular arrhythmias during ischemia-reperfusion injury when started pre-MI. No information exists regarding their efficacy and safety when started pre-MI and continued peri- and post-MI. We evaluated whether the ARB losartan improves the outcome when started pre-MI and continued peri- and post-MI. Male Wistar rats ( n = 502) were treated for 7 days pre-MI with losartan at a high dose (30 mg·kg−1·day−1), progressively increasing dose (3 mg·kg−1·day−1 increased to 10 mg·kg−1·day−1 10 days and 30 mg·kg−1·day−1 20 days post-MI), or no treatment. Ambulatory systolic blood pressure and Holter monitoring were performed for 24 h post-MI. Echocardiography was done 30 days post-MI, and LV remodeling, cardiac hemodynamics, and fetal gene expression were assessed 38 days post-MI. High-dose losartan reduced 24-h post-MI survival compared with the progressive dose and control (21.9% vs. 36.6% and 38.1%, P = 0.033 and P = 0.009, respectively). This was associated with greater hypotension in the high dose and no change in ventricular arrhythmias in all groups. In 24-h post-MI survivors, the progressive dose group had reduced mortality from 24 h to 38 days (8.5% vs. 28.6% for control vs. 38.9% for high dose, P = 0.032 and P = 0.01, respectively). Survivors of both losartan groups demonstrated improved LV remodeling, cardiac hemodynamics, preserved GLUT-4, and reduced cardiac fetal gene expression. Pretreatment with ARBs does not reduce 24-h post-MI ventricular arrhythmias or survival, and high doses increase mortality by causing excessive hypotension. In 24-h post-MI survivors, progressively increasing doses of losartan have multiple beneficial effects, including improved survival.Keywords
This publication has 29 references indexed in Scilit:
- What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?American Heart Journal, 2003
- HEART FAILURE: Angiotensin receptor blockers for chronic heart failure and acute myocardial infarctionHeart, 2001
- ANIMAL MODELS OF CHRONIC HEART FAILUREPharmacological Research, 2000
- Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykininCardiovascular Research, 1998
- The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in ratsCardiovascular Research, 1996
- Survival after myocardial infarction in rats: captopril versus losartanJACC, 1996
- Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarctionJournal of Molecular and Cellular Cardiology, 1995
- Markedly different effects on ventricular remodelling result in a decrease in inducibility of ventricular arrhythmiasJACC, 1994
- Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemiaCardiovascular Research, 1988
- Significance of hypotension preceding fatal ventricular tachyarrhythmias in post-coronary obstruction sudden deathAmerican Heart Journal, 1981